#Pardes biosciences registration

#Pardes biosciences registration

II, Pardes and the business combination.В After the registration statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to shareholders of FS Development Corp. II are urged to read, the preliminary proxy statement/ prospectus as well as other documents filed with the SEC because these documents will contain important information about FS Development Corp. Before making a voting decision, investors, shareholders and other interested persons of FS Development Corp. Securities and Exchange Commission (вЂњSECвЂќ) a registration statement on Form S-4, which includes a description of the terms of the business and includes a prospectus with respect to the combined companyвЂ™s securities to be issued in connection with the business combination and a proxy statement with respect to the shareholder meeting of FS Development Corp. In connection with the Merger Agreement, FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital. On June 29, 2021, Pardes entered into a definitive Agreement and Plan of Merger (the вЂњMerger AgreementвЂќ) with FS Development Corp. For more information, visit Additional Information and Where to Find It Pardes Biosciences is headquartered in Carlsbad CA. This protease is highly similar across all coronaviruses, including known and emerging coronavirus variants. PBI-0451 is designed to inhibit the coronavirus main protease, an essential protein for SARS-CoV-2 replication. The companyвЂ™s lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections. Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. Pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the worldвЂ™s most pressing public health challenges. вЂњThis issued patent is the first from our growing IP portfolio and reflects our commitment to discovering and developing novel therapies for important unmet medical needs.вЂќ We believe that oral antivirals have the potential to play an important role in ending this pandemic and preventing the next one, and we are committed to developing viral protease inhibitors as potential oral therapies for SARS-CoV-2 infections.вЂќ said Uri Lopatin, Chief Executive Officer of Pardes. вЂњWe are pleased with the progress in our IP portfolio and our program developments to date. The вЂ497 patent covers compounds designed to inhibit an essential viral protein, the main protease (Mpro) of SARS-CoV-2, the virus causing COVID-19.

11,124,497 (the вЂњвЂ™497 patentвЂќ), strengthening the CompanyвЂ™s intellectual property position for the CompanyвЂ™s antiviral drug development program. Patent and Trademark Office has issued a new patent No. 21, 2021 (GLOBE NEWSWIRE) - Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company,В today announced that the U.S.